Reaction

Exposure Via Breast Milk reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,863 reports · 97 co-occurring drugs

As of the last recalculation, Exposure Via Breast Milk appears in 3,863 FAERS reports alongside 97 co-occurring drug terms. The strongest observed disproportionality signal is NICOTINE POLACRILEX MINI (PRR 46.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Nicotine Polacrilex Mini	126	46.7	47.1
Nicotine Polarilex	126	46.7	47.1
Nevirapine	36	21.7	21.8
Buprenorphine Hydrochloride, Naloxone Hydrochloride	89	20.3	20.4
Nicotine Polacrilex	126	18.3	18.4
Nicotine	126	17.3	17.4
Labetalol	36	14.7	14.7
Lamotirigine	183	14.4	14.4
Lamotrigine Extended-Release	183	14.4	14.4
Lamotrigine Chewable Dispersible	183	14.4	14.4
Ursosiol	46	12.9	12.9
Docusate Sodium 100Mg	56	12.8	12.8
Zidovudine	31	12.6	12.6
Certolizumab Pegol	238	11.6	11.6
Ursodiol	46	11.5	11.5
Agalsidase Beta	19	11.1	11.1
Methadone Hydrochloride	20	10.0	10.0
Elexacaftor, Tezacaftor, And Ivacaftor	23	10.0	10.0
Lamotrigine	215	9.3	9.3
Levetiracetam In Sodium Chloride	123	8.8	8.8
Levetiracetam Oral	123	8.8	8.8
Levetiracetam Injection	123	8.8	8.8
Tramadol Hydrochloride	59	8.6	8.6
Phytonadione	13	8.3	8.3
Methylphenidate	44	8.3	8.3
Copper	65	8.2	8.3
Lamivudine Oral	38	8.2	8.2
Tenofovir Disoproxil Fumarate Tablets	13	8.1	8.1
Dimenhydrinate	15	7.6	7.6
Methadone	58	7.4	7.4
Acetaminophen And Codeine	16	7.1	7.1
Fentanyl Citrate	23	7.0	7.0
Oxymorphone Hydrochloride	15	7.0	7.0
Cyclobenzaprine	62	6.8	6.8
Lamivudine	38	6.7	6.7
Levetiracetam	158	6.6	6.6
Ferrous Sulfate	60	6.5	6.5
Buprenorphine	109	6.5	6.5
Lisdexamfetamine Dimesylate	37	6.1	6.1
Clobazam	27	6.0	6.0
Methylphenidate Hydrochloride	64	5.9	5.9
Cariprazine	10	5.8	5.8
Docusate Sodium	61	5.8	5.8
Doxepin Hydrochloride	12	5.1	5.1
Escitslopram	53	5.0	5.0
Duloxetine	63	4.9	4.9
Sodium Oxybate	59	4.9	4.9
Efavirenz	10	4.8	4.8
Vedolizumab	75	4.8	4.8
Escitalopram Oxalate	61	4.6	4.6
Ampicillin	7	4.6	4.6
Ampicillin Sodium	7	4.6	4.6
Nifedipine	39	4.5	4.5
Oxycodone Hydrochloride And Acetaminophen	78	4.3	4.3
Bupropion	35	4.3	4.3
Venlafaxine	56	4.3	4.3
Rimegepant Sulfate	10	4.3	4.3
Doxepin	8	4.3	4.3
Lacosamide	29	4.2	4.2
Brivaracetam	7	4.2	4.2
Gentamicin	10	4.1	4.1
Aripiprazole Oral	31	4.1	4.1
Aripiprazole Orally Disintegrating	31	4.1	4.1
Sertraline	86	4.0	4.0
Calcium, Magnesium, Potassium, And Sodium Oxybates	6	3.8	3.8
Triamcinolone Acetonide Ointment Usp, 0.05%	16	3.7	3.7
Aripiprazole	82	3.7	3.7
Biotin	20	3.5	3.5
Risankizumab-Rzaa	51	3.4	3.4
Triamcinolone Acetonide	19	3.3	3.3
Ustekinumab	61	3.2	3.2
Glatiramer Acetate	35	3.2	3.2
Ocrelizumab	35	3.1	3.1
Phenobarbital	8	3.0	3.0
Bupivacaine	5	2.9	2.9
Eculizumab	28	2.8	2.8
Tenofovir Disoproxil Fumarate	17	2.8	2.8
Morphine Sulfate	53	2.4	2.4
Botulinum Toxin Type A	5	2.2	2.2
Lurasidone Hydrochloride	8	2.1	2.1
Peginterferon Beta-1A	5	2.1	2.1
Ivacaftor	3	2.0	2.0
Brexpiprazole	6	1.9	1.9
Ofatumumab	12	1.9	1.9
Vortioxetine	6	1.9	1.9
Dupilumab	166	1.9	1.9
Romiplostim	5	1.8	1.8
Ravulizumab	4	1.6	1.6
Glecaprevir And Pibrentasvir	3	1.5	1.5
Natalizumab	47	1.4	1.4
Guselkumab	9	1.4	1.4
Sarilumab	6	1.2	1.2
Onabotulinumtoxina	17	1.2	1.2
Erenumab-Aooe	10	1.0	1.0
Etonogestrel	8	0.9	0.9
Salicylic Acid	3	0.3	0.3
Adapalene	9	0.3	0.3

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.